Friday, 06 Dec 2019

You are here

T2T Improves Primary Care Gout Management

Researchers from Geisinger Medical center tested a pilot primary care gout management improvement intervention, and demonstrated significantly improved primary care gout management metrics when a treat to target approach was implemented. 

They studied 2 large primary care sites - one underwent the intervention, the other/control, did not. The gout management plan ("intervention") included education of the intervention staff and EMR to assess outcomes; 1) percent of gout patients treated with urate lowering therapy; 2) percent of treated patients monitored with serum urate; and 3) percent of treated patients at target serum urate ≤ 6.0 mg/dl. The intervention site providers received monthly performance reports compared to their peers.

At 6 months, the intervention site significantly improved all 3 gout performance measures.

  • ULT use increased from 54.4 to 61.1%, OR 1.19 (95% CI 1.08, 1.31 and p-value <0.001);
  • Monitoring increased from 56.1 to 79.2% OR 1.52 (95% CI 1.24, 1.87 and P-value <0.001);
  • Achieving a T2T goal (< 6.0)  increased from 26.8 to 43.3% OR 1.43 (95% CI 1.16, 1.77 and p-value <0.001.

At 6 months gout patients at the intervention site were 3.5 times more likely to be monitored and 2 times more likely to achieve their urate goal (p-value <0.001) than control site patients.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.

PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout

Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.

T2T Lowers Mortality in Gout

A Spanish prospective cohort of active, uncontrolled gout patients were followed and showed that failure to reach a target serum uric acid (sUA) level of 6 mg/dl (0.36 mmol/L) or less was associated with a 2-3 fold increase in mortality.

Novel Inhibition of MSU Crystal Inflammation

Researchers from Washington State University have shown that inhibition of tumor growth factor-β (TGF-β)-activated kinase 1 (TAK1) can effectively downregulate inflammatory mediators and suppress inflammation caused by gout.

Monosodium urate (MSU) crystals directly activate the inflammasome to produce a plethora of pro-inflammatory cytokines, including interleukin-1β (IL-1β). 

Patients Prefer Nurse Led Care for their Gout

Despite the well known, well publicized treat-to-target (T2T) goal of a serum uric acid (SUA) level < 6 mg/dl, this goal is seldom achieved (< 40%) in clinical practice and patient adherence has been unacceptably low. A recent study shows that nurse-led care led to better outcomes in gout including patient acceptability, long-term adherence, and less flares.